Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

NCT03547973 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

827

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Urothelial Cancer

Interventions

DRUG: Sacituzumab Govitecan-hziy
DRUG: Pembrolizumab
DRUG: Cisplatin
DRUG: Avelumab
DRUG: Zimberelimab
DRUG: Carboplatin
DRUG: Gemcitabine
DRUG: Domvanalimab
DRUG: Enfortumab Vedotin

Sponsor

Gilead Sciences

Collaborators

[object Object]